Home › Hidradenitis Suppurativa › Massachusetts
Hidradenitis Suppurativa clinical trials in Massachusetts
10 studies for Hidradenitis Suppurativa are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Beth Israel Deaconess Medical Center - Boston- Site Number : 8400001, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07225569Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
- Clinical Site 3, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07828860A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
- Up0122 104, Boston
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 18, 2026 · NCT06888193Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Investigative Site US030, Boston
- Investigative Site US048, Brighton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06855498Targeting Nociceptors in Hidradenitis Suppurativa
- University of Massachusetts Chan Medical School, Worcester
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Sep 10, 2026 · NCT05403710Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- Boston Childrens Hospital, Boston
RecruitingPhase 2
Ages 12 to 17 · All sexes · Updated Aug 6, 2026 · NCT07213973A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 22, 2026 · NCT07384975The Safety and Efficacy of Roflumilast Foam in HS
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07263230A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
RecruitingObservational study
Ages 18 to 71 · All sexes · Updated Apr 16, 2026 · NCT07123038A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 6, 2026 · NCT07244263From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.